Table 2.
Result comparison of GGEA and FiDePa application to the glioma dataset
| Pathway | ORA P (GGEA) | ORA P (FiDePa) | Rank (FiDePa) |
|---|---|---|---|
| ↑ Pathways in cancer | 1.8e-24 | – | – |
| ↑ Focal adhesion | 1.4e-18 | 2.5e-06 | 5 |
| ↑ T cell receptor signalling | 1.2e-17 | 1.5e-05 | 7 |
| ↑ Neurotrophin signalling | 5.5e-15 | – | – |
| ↑ Colorectal cancer | 1.1e-14 | 9.4e-05 | 11 |
| ↑ Pancreatic cancer | 3.8e-14 | 0.0001 | 12 |
| ↑ Renal cell carcinoma | 1.3e-13 | – | – |
| ↑ VEGF signalling | 1.5e-13 | 0.006 | 22 |
| ↔ Fc epsilon RI signalling | 4.1e-13 | 1.9e-05 | 9 |
| ↓ Chronic myeloid leukaemia | 6.3e-13 | 1.65e-05 | 8 |
| ↑ ErbB signalling | 8.9e-13 | – | – |
| ↑ B cell receptor signalling | 4.2e-12 | 0.001 | 17 |
| ↑ Glioma | 5.1e-12 | 0.003 | 20 |
| ↑ Insulin signalling | 3.2e-11 | 0.001 | 18 |
| ↑ Leucocyte transendothelial migration | 3.9e-11 | 0.01 | 24 |
| ↓ Adherens junction | 4.9e-11 | 1.4e-05 | 6 |
| ↓ GnRH signalling | 6.5e-11 | 0.0003 | 16 |
| ↓ Nature killer cell mediated cytotoxicity | 6.5e-11 | 1.4e-11 | 2 |
| ↑ Wnt signalling | 1.2e-10 | – | – |
| ↓ Toll-like receptor signalling | 1.2e-09 | 5.5e-05 | 10 |
| ↑ Endometrial Cancer | 1.6e-07 | – | – |
| ↑ Non-small cell lung cancer | 3.4e-07 | – | – |
| ↑ Acute myeloid leukaemia | 3.9e-07 | – | – |
| ↓ mTOR signalling | 1.2e-06 | 0.0002 | 15 |
| ↓ MAPK signalling | 4.4e-06 | 1.6e-25 | 1 |
| … | … | … | … |
| ↓ Apoptosis | 0.04 | 9.3e-11 | 3 |
Arrows in the first column denote whether a pathway is ranked higher or lower by GGEA, compared with FiDePa.